Means Investment CO. Inc. Reduces Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Means Investment CO. Inc. lessened its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 24.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,829 shares of the company's stock after selling 12,211 shares during the quarter. Means Investment CO. Inc.'s holdings in Hims & Hers Health were worth $1,118,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the period. Renaissance Technologies LLC raised its stake in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after buying an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Hims & Hers Health by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after buying an additional 40,447 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $3.40 during mid-day trading on Friday, hitting $64.47. 42,122,835 shares of the company were exchanged, compared to its average volume of 21,531,466. The stock has a market cap of $14.43 billion, a price-to-earnings ratio of 93.44, a price-to-earnings-growth ratio of 2.30 and a beta of 2.09. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The company has a 50 day moving average of $47.68 and a 200-day moving average of $38.96.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. Hims & Hers Health's quarterly revenue was up 110.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.05 EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on HIMS shares. Citigroup reissued a "sell" rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Leerink Partners increased their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $61.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $38.00.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 36,460 shares of the company's stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $28.04, for a total transaction of $1,022,338.40. Following the completion of the sale, the chief executive officer now owns 92,103 shares of the company's stock, valued at approximately $2,582,568.12. This represents a 28.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 3,236 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $27.77, for a total value of $89,863.72. Following the transaction, the insider now owns 170,285 shares in the company, valued at approximately $4,728,814.45. This represents a 1.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 751,034 shares of company stock worth $36,486,522. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.